M. Tomirotti

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 476 citations

Second-line Treatment, Oncology, Wild-type Egfr Tumours +9

Complications of Subcutaneous Infusion Port in the General Oncology Population

C Ballarini, Mattia Intra, Andrea Pisani Ceretti et al. · Oncology · 1999 · 129 citations

Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients

Andrés J.M. Ferreri, Michele Reni, Stefania Dell’Oro et al. · Oncology · 2001 · 94 citations

TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

Marina Chiara Garassino, Olga Martelli, Anna Bettini et al. · Journal of Clinical Oncology · 2012 · 54 citations

Surgical Oncology, Cancer Management, Pathology +18

Serum Copper and Ceruloplasmin Levels in Patients with Neoplasias Localized in the Stomach, Large Intestine or Lung

A. Scanni, Luciano Licciardello, Marinella Trovato et al. · Tumori Journal · 1977 · 43 citations

Serum Copper, Gastrointestinal Oncology, Medicine +11